Merck & Co Inc at Goldman Sachs CEOs Unscripted Conference Transcript
Good morning, and happy new year to everybody. My name is Chris Shibutani. I'm the U.S. large cap pharmaceuticals analyst, and I also cover some of the biotech and biopharma sector. So I was really pleased to see the expectations for performance out of both of those.
Me, too.
Outstanding. We are thrilled to kick off the year. Literally, this is the start of the year, and with Merck being able to be the first voice as the industry and the investor community comes together once again, and we look forward to 2023, where, obviously, expectations for performance there.
Really pleased to have joining with us Rob Davis, CEO, and now Chairman as well, which, I think, is an interesting context. Also our slide should be updated for that. But I also did want to express special thanks to the entire
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
